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among men: a systematic review and meta-analysis
of placebo-controlled randomized trials
Lin Xu1, Guy Freeman1, Benjamin J Cowling1 and C Mary Schooling1,2*Abstract
Background: Testosterone therapy is increasingly promoted. No randomized placebo-controlled trial has been
implemented to assess the effect of testosterone therapy on cardiovascular events, although very high levels of
androgens are thought to promote cardiovascular disease.
Methods: A systematic review and meta-analysis was conducted of placebo-controlled randomized trials of
testosterone therapy among men lasting 12+ weeks reporting cardiovascular-related events. We searched PubMed
through the end of 2012 using “(“testosterone” or “androgen”) and trial and (“random*”)” with the selection limited
to studies of men in English, supplemented by a bibliographic search of the World Health Organization trial registry.
Two reviewers independently searched, selected and assessed study quality with differences resolved by consensus.
Two statisticians independently abstracted and analyzed data, using random or fixed effects models, as appropriate,
with inverse variance weighting.
Results: Of 1,882 studies identified 27 trials were eligible including 2,994, mainly older, men who experienced 180
cardiovascular-related events. Testosterone therapy increased the risk of a cardiovascular-related event (odds ratio
(OR) 1.54, 95% confidence interval (CI) 1.09 to 2.18). The effect of testosterone therapy varied with source of
funding (P-value for interaction 0.03), but not with baseline testosterone level (P-value for interaction 0.70). In trials
not funded by the pharmaceutical industry the risk of a cardiovascular-related event on testosterone therapy was
greater (OR 2.06, 95% CI 1.34 to 3.17) than in pharmaceutical industry funded trials (OR 0.89, 95% CI 0.50 to 1.60).
Conclusions: The effects of testosterone on cardiovascular-related events varied with source of funding.
Nevertheless, overall and particularly in trials not funded by the pharmaceutical industry, exogenous testosterone
increased the risk of cardiovascular-related events, with corresponding implications for the use of testosterone
therapy.
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In observational studies low serum testosterone is associ-
ated with cardiovascular disease [1,2]. Testosterone may
protect or be a secondary risk marker of other processes
[1-3]. On the precautionary principle, expert advice and
reviews, largely based on observational evidence, warn that
cardiovascular disease may be increased by androgen
deprivation therapy [4] and low testosterone [5,6]. Awareness* Correspondence: mschooli@hunter.cuny.edu
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reproduction in any medium, provided the orof low testosterone as a treatable condition is being raised
[7,8]. Testosterone use is increasing [9-11], possibly as
self-medication in response to advertising.
In 2004 the Institute of Medicine (IOM) reviewed the
evidence on testosterone therapy and concluded, largely
based on placebo-controlled trials, that ‘there is not clear
evidence of benefit for any of the health outcomes exam-
ined’ [12]. The IOM recommended small-scale trials to es-
tablish the efficacy of testosterone therapy where other
treatments were not available [12]. To our knowledge, no
trial has been designed to assess the effect of testosterone
therapy on cardiovascular morbidity or mortality. PreviousThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that testosterone therapy resulted in a non-significantly
higher risk of cardiovascular events, based on adverse events,
but only included trials through March 2005 [13,14]. A more
recent meta-analysis included trials through August 2008
but only reported on three specific cardiovascular outcomes,
that is, arrhythmia, coronary bypass surgery and myocardial
infarction [15]. Given the widespread use of testosterone,
the high prevalence of cardiovascular disease in older men
and no comprehensive assessment of the effect of testos-
terone therapy on cardiovascular events, an up-to-date
meta-analysis may help inform clinical practice. We car-
ried out a meta-analysis of adverse events from rando-
mized placebo-controlled trials to examine the overall
risk of cardiovascular-related events associated with tes-
tosterone therapy.
Methods
This meta-analysis follows the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
checklist [see Additional file 1] and a published protocol
(CRD42011001815) [16]. Two reviewers (LX and CMS)
independently searched for and selected trials, resolving
any differences by consensus. Two statisticians (GF and
BJC) extracted information from the selected trials.
Data sources and searches
We (LX and CMS) systematically searched PubMed until
31st December 2012 using “(“testosterone” or “androgen”)
and (random*) and trial” with the selection limited to
studies in men in English, because a preliminary search
only found studies in English. We (LX and CMS) searched
the World Health Organization (WHO) International
Clinical Trials Registry Platform for any trial using testos-
terone as an intervention. From this search, we (LX and
CMS) discarded any studies both agreed were irrelevant
based on title or abstract and read the remaining. We did
a bibliographic search of the selected trials and relevant
reviews.
Study selection
We included randomized placebo-controlled trials giving
cardiovascular-related events by study arm, because a re-
port may focus on a particular aspect of the trial [17,18]
and not report all events that have occurred [17-19]. We
excluded trials that only gave treatment-related events in
the testosterone arm because these might not include
full reporting of events in the placebo arm. Initially, we
intended to exclude trials that only reported withdrawals
as potentially less comprehensive than reporting of
adverse events [18,19], however this turned out to be a
very fine distinction, so we included any trial reporting
cardiovascular-related events by study arm.We included any randomized controlled trial (RCT) of
testosterone, but not other androgens, compared with
placebo, including a comparison against a background of
other treatments, because men likely to be taking testos-
terone may also be in treatment for other conditions.
We excluded trials of less than twelve weeks’ duration to
assess long-term rather than acute effects of testosterone
therapy.
We checked for duplication based on overlapping
authorship, study description, number of participants and
participant characteristics. When duplication occurred we
used the study with the most comprehensive description
of adverse events.
Outcome
The primary outcome was composite cardiovascular-
related events; because we anticipated too few events for
robust assessment by cardiovascular event type; and a
system-wide composite outcome may be most suitable
for adverse events [20]. Cardiovascular-related events
were defined as anything reported as such by the au-
thors, that is, events reported as cardiac disorders, car-
diovascular complaints, cardiovascular events, vascular
disorders, cardiac or cardiovascular, or where the event
description fell within the International Statistical Classi-
fication of Disease (ICD) version 10 chapter IX (I00 to
I99). Most trials only reported serious adverse events,
but a few also reported a wider range of events, so we
also examined the effect of testosterone therapy by ser-
iousness. Seriousness was based on the US Department
of Agriculture definition of serious adverse events and
the type of cardiovascular event generally considered
serious [21]. Serious cardiovascular events were defined
as cardiovascular-related events which the authors de-
scribed as serious adverse events or where the outcome
was death, life-threatening, hospitalization, involved per-
manent damage or required medical/surgical interven-
tion, or was one of the following types of cardiovascular
event: myocardial infarction, unstable angina, coronary
revascularization, coronary artery disease, arrhythmias,
transient ischemic attacks, stroke or congestive heart
failure but not deep vein thrombosis.
Data extraction and quality assessment
A statistician (GF) extracted the number of participants
randomized and cardiovascular-related events by trial
arm. Event classification was checked by a physician (LX).
A second statistician (BJC) checked the information
extracted. Where trials reported cardiovascular-related
events without giving the study arm, we contacted the
authors twice by email to ask for cardiovascular-related
events by study arm.
The reviewers (LX and CMS) independently used an
established tool to evaluate the quality of each trial [22],
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related adverse events. First, we reported whether car-
diovascular-related events were individually listed in a
table by study arm, because these are easier to identify
unambiguously. Second, we reported whether the type
and severity of cardiovascular-related events reported
was either pre-specified or identified before the alloca-
tion was revealed, because issues have been expressed
about the reporting of adverse events [23,24]. Cardiovascular-
related events vary in severity making the selection criteria
and categorization crucial to an outcome assessed from
adverse events.
Sensitivity analysis
We initially planned only to assess whether the effects of
testosterone on cardiovascular-related events varied with
average baseline testosterone, because we did not expect
sufficient trials for sub-group analysis by type of testos-
terone product or by type of cardiovascular-related
event. However, the reporting of adverse events may beCitations identified from electronic
searches on PubMed
(n=1882)
Potentially relevant articles
retrieved for detailed examination
(n=169)
A
e
Final inclusion for the
systematic review
(n=27)
Figure 1 Selection process for the placebo-controlled randomized trials
events.open to interpretation [23], and may not be comprehen-
sive [25]. Given potential lack of clarity as to the selection
of the cardiovascular-related adverse events reported, we
also examined whether the effect of testosterone therapy
varied with funding source. Finally, we also considered
cardiovascular-related death as an outcome.
Data synthesis and analysis
We used the number of participants randomized as the de-
nominator and included all cardiovascular-related events
from the start. We used funnel plots and ‘trim and fill’ to
assess publication bias, that is, missing trials. We used I2 to
assess heterogeneity between trials, using fixed effects
models where there was low heterogeneity (I2 <30%), other-
wise using random effects models. We obtained the pooled
odds ratio, using the ‘metabin’ function of the ‘meta’ pack-
age in R 2.14.1 (R Development Core Team, Vienna,
Austria). We used meta-analysis regression, with inverse
variance weighting, to assess whether the effects of testos-
terone therapy varied with baseline testosterone or fundingCitations clearly not relevant
based on abstract and/or title
(n=1713)
rticles excluded (no cardiovascular-related
vents by trial arms, intervention <12 weeks,
no control group, not RCT), duplicate
(n=138)
Articles with events identified
from previous meta-analysis
(n=2)
Articles found from
WHO International Clinical Trial Registry
(n=1)
Articles found from bibliography
of selected articles
(n=0)
Articles excluded as no clarification
from authors
(n=7)
of the effects of testosterone therapy on cardiovascular-related
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R 2.14.1. Initial analysis showed the pooled odds ratio was
similar using a Peto or a Mantel-Haenszel estimate; we
used inverse variance weighting for consistency with the
meta-regression.
This study is an analysis of published data, which does
not require ethics committee approval.
Results
The initial search yielded 1,882 papers, of which 169 were
selected for full text scrutiny. Of these 169 papers, 31
concerned different placebo-controlled randomized trials
among men of testosterone therapy of 12+ weeks
reporting cardiovascular-related events by study arm. We
found one additional recent trial from the WHO Inter-
national Clinical Trials Registry Platform [26]. We did not
find any additional such trials from a bibliographic search
of these 32 papers or from eight reviews [27-34]. Two
additional trials [35,36] selected for full text scrutiny had
cardiovascular-related events shown in a plot from one
previous meta-analysis [13], but not the other meta-
analyses [14,15] or in the relevant publications [35-37].
The search did not find one small non-randomized trial
[38] included in two previous meta-analyses [13,15]. The
search found one additional trial [39] potentially relevant
to the earlier meta-analyses [13,14], two additional trials
[40,41] potentially relevant to the most recent meta-
analysis [15] and 11 subsequent trials. We sought clarifica-
tion concerning events by study arm for 10 trials as set
out in Additional file 2. Six authors never responded
[37,40,42-45], three responded but did not provide any
relevant information [36,46,47] and one provided informa-
tion [48]. We included this later trial [48], one of the
others that gave cardiovascular deaths, but not other
cardiovascular-related events, by study arm [46] and one
that gave vascular events, but not all cardiovascular-
related events by study arm [44]. Figure 1 shows the
search strategy resulting in 27 placebo-controlled random-
ized trials.
Table 1 shows the 27 trials over 25 years of 2,994 mostly
middle-aged or older men (1,733 testosterone and 1,261
placebo) with low testosterone and/or chronic diseases,
who experienced 180 cardiovascular-related events. Most
of the trials were in Western settings. Thirteen trials were
supported by the pharmaceutical industry. Two trials were
stopped early [49,50], one because of adverse events
among the men allocated to testosterone [50] and one
because ‘it would not be feasible to demonstrate - in the
foreseeable future - a beneficial effect of testosterone [on
mortality] by continuing the study’ [49].
Quality assessment
The quality assessment (see Additional file 3) shows that
two trials provided a table with a comprehensive list ofcardiovascular-related events by study arm and eight trials
provided a summary table of cardiovascular-related events
by study arm. For 17 trials cardiovascular-related events
were surmised from withdrawals and/or adverse events as
given in Additional file 4, including one where the
cardiovascular-related events were surmised from a P-
value [65]. The type and severity of adverse events to be
reported was pre-specified in one trial [61]. In the two tri-
als terminated early the adverse events motivated termin-
ation and were identified before treatment allocation was
known [49,50]. Otherwise it was sometimes unclear
whether the definition or classification was made by
masked assessors.
Data synthesis
The funnel plot (Figure 2) shows several small studies
(on the left hand side) where testosterone reduced
cardiovascular-related events, however, there were no
similar small studies where testosterone increased
cardiovascular-related events. The forest plot (Figure 3)
shows that the trials were homogeneous (I2 = 7.8%).
Testosterone increased the risk of a cardiovascular-
related event in a fixed effect model, odds ratio (OR)
1.54, 95% confidence interval (CI) 1.09 to 2.18. Trim
and fill revised the OR to 1.69 (95% CI 1.21 to 2.38).
When the analysis was restricted to serious events,
whose categorization is shown in Additional file 4, the
estimate was very similar (OR 1.61 (95% CI 1.01 to
2.56)) and was revised to 2.01 (95% CI 1.30 to 3.14) by
trim and fill.
Sensitivity analysis
The cardiovascular-related event rate was lower in trials
funded by the pharmaceutical industry (4% (66/1,651))
than in other trials (8% (114/1,343)). In a meta-regression
model, risk of cardiovascular-related events on testosterone
therapy varied with the source of funding (P-value for
interaction 0.03) but not with baseline testosterone
(P-value for interaction 0.70). In trials funded by the
pharmaceutical industry testosterone had no effect on
cardiovascular-related events, but in the other trials
testosterone therapy substantially increased the risk of
a cardiovascular-related event (Figure 4). Finally, 33
cardiovascular-related deaths were identified (22 testos-
terone arm and 11 placebo arm), for which the odds
ratio was similar 1.42 (95% CI 0.70 to 2.89) to the es-
timate for all cardiovascular-related events, and was
revised to 1.57 (95% CI 0.78 to 3.13) by trim and fill.
Discussion
This updated meta-analysis of placebo-controlled ran-
domized trials, with a much larger number of partici-
pants than previous meta-analyses [13-15], adds to the
previous findings by showing that testosterone therapy
Table 1 Characteristics of placebo-controlled randomized trials giving the effects of testosterone therapy on cardiovascular-related events among men
Author and publication
year
Study Participants Industry funding
Setting Duration Dose Cardiovascular-related
events based on
Age
range
Number Health status Initial T
(nmol/L)
Copenhagen Study
Group [49] 1986
Denmark About 16
monthsa
200 mg/8 h micronized T, PO Deaths 24 to 79 221 alcoholic cirrhosis about 20 None given
Marin [39] 1993 Denmark 9 months T gel 125 mg/day Withdrawals 40 to 65 21 Obese, low T 15.3 Funded by Besins
Iscovesco
Hall [51] 1996 UK 9 months T enanthate 250 mg /month,
IM
Withdrawals 34 to 79 35 Rheumatoid
arthritis
16.1 Funded by Schering
Healthcare
Sih [52] 1997 US 12 weeks T cypionate IM every 14 to
17 days
Withdrawals 51 to 79 32 T<60 ng/dl 9.2 None given
English [53] 2000 UK 12 weeks Transdermal T 5 mg/day Withdrawals and safety data Mean 62 50 Coronary artery
disease
12.9 Patches given by
Smith Kline Beecham
Snyder [19] 2001 US 36 months Transdermal T 6 mg/day Clinically apparent from
hospital records
65+ 108 Men with T one
SD <475 ng/dl
12.7 Patches given by
ALZA Corporation
Amory [54] 2004 US 36 months T enanthate 200 mg/2 weeks,
IM
Serious adverse
cardiovascular events
65 to 83 48 TT <350 ng/dl 10 None given
Kenny [55] 2004 US 12 weeks T enanthate 200 mg/3 weeks,
IM
General description 73 to 87 11 Cognitive decline,
bioavailable T
<128 ng/dl
14.1 None
Svartberg [56] 2004 Norway 26 weeks T enanthate 250 mg/month,
IM
General description Mean 66 29 COPD 21.1 None
Brockenbrough [57]
2006
US 6 months Transdermal T gel 10 g/day Side effects and adverse
events
Mean 56 40 Dialysis and TT
<300 ng/dl
7.3 Supported by
Auxilium
Pharmaceuticals
Malkin [58] 2006 UK 12 months Transdermal T patch 5 mg/day Serious adverse events Mean 64 76 Heart failure 13.0 Medication given by
Watson
Pharmaceuticals
Merza [59] 2006 UK 6 months Transdermal T patch 5 mg/day Withdrawals 40+ 39 TT <10 nmol/L 8.0 Supported by Ferring
Pharmaceuticals Ltd
Nair [60] 2006 US 24 months Transdermal T patch 5 mg/day Adverse events 60+ 62 DHEA<1.57 μg/ml,
bioavailable T
<103 ng/dl
13.7 Supported by The
Endocrine Society
Emmelot-Vonk [61]
2008
Netherlands 6 months TU 160 mg/day, PO Adverse events 60 to 80 237 TT<13.7 nmol/L 10.7 Medication given by
Organon NV
Svartberg [41] 2008 Norway 52 weeks TU 1000 mg, MI at 0, 6, 16, 28
and 40 weeks
Deaths 60 to 80 38 TT≤11.0 nmol/L 8.3 Grant from Bayer
Schering Pharma AG
Caminiti [62] 2009 Italy 12 weeks TU 1000 mg MI for 0, 6 and
12 weeks
General description of events 66 to 76 70 Heart failure 7.0 None given
Chapman [48] 2009 Australia 1 year TU 80 mg orally twice a day Hospitalizations 65+ 23 Undernourished 18.8 Organon provided
funding
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Table 1 Characteristics of placebo-controlled randomized trials giving the effects of testosterone therapy on cardiovascular-related events among men
(Continued)
Legros [46] 2009 Europe 1 year TU 80, 160 and 240 mg orally
per day
Safety assessments 50+ 316 Free T<0.26 nmol/
L
12.8 Funded by Schering-
Plough
Aversa [63] 2010 Italy 24 months TU 1,000 mg (every 12 weeks) Safety aspects 45 to 65 50 MS and/or T2DM
TT<3.0 ng/ml
8.5 None given
Basaria [50] 2010 US About 6
monthsa
Transdermal T gel 100 mg/day Cardiovascular-related events 65+ 209 Frial, TT 100 to
350 ng/dl
8.4 Medication given by
Auxilium
Pharmaceuticals
Srinivas-Shankar [64]
2010
US 6 months Transdermal T gel 50 mg/day Serious adverse events and
withdrawals
65+ 274 TT≤12 nmol/L
(345 ng/dl)
11.0 Supported by Bayer
Schering Pharma
Jones [65] 2011 Europe 12 months T gel 60 mg/day Cardiovascular events 37 to 88 220 Hypogonadal with
type 2 diabetes
and/or MetS,
9.4 Supported by
ProStrakan
Ho 2011 [66] Malaysia 1 year TU 1000 mg MI for 0, 6, 18, 30
and 42 weeks
Withdrawals 40+ 120 T<12 nmol/L, 9.0 Supported by Bayer
Schering Pharma
Kaufman [44] 2011 US 182 days 1.62% T gel 2.5 mg/day Safety aspects 45 to 64 274 Hypogonadal,
T<300 ng/dl
9.8 Funded by Abbott.
Kalinchenko [67] 2010 Russia 30 weeks TU 1,000 mg MI for 0, 6, 18
and 30 weeks
Withdrawal 35 to 70 184 T<350 ng/dl 7.0 Supported by Bayer
Schering Pharma
Hoyos [68] 2012 Australia 18 weeks TU 1000 mg MI at 0, 6 and
12 weeks
Adverse events 18+,
mean 49
67 Obese men with
obstructive sleep
apnea
13.3 Supported by Bayer
Schering Pharma
Spitzer [26] 2012 US 14 weeks 1% T gel 10 g/day Adverse events 40 to 70 140 Erectile
dysfunction low T
and a sexual
partner
12.3 none
atrial stopped early so duration varies. IM= intramuscularly; P, placebo; PO, orally; T= testosterone; TT= total testosterone; TU= testosterone undecanoate.
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Testosterone       Favours    Placebo
Figure 2 Funnel plot of placebo-controlled randomized trials
examining the effects of testosterone therapy on
cardiovascular-related events.
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risk of testosterone therapy was particularly marked in
trials not funded by the pharmaceutical industry. The
risks of cardiovascular-related events were similar by base-
line testosterone.
Several possible explanations exist for our findings.
First, not all trials of testosterone therapy reported
all cardiovascular-related events by study arm [36,46].Study
Fixed effect model
Heterogeneity: I-squared=7.8%, tau-squared=0.0742, p=0.3484
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Figure 3 Forest plots of placebo-controlled randomized trials examin
cardiovascular-related events.Trials favoring testosterone may be unpublished. How-
ever, the funnel plot (Figure 2) and ‘trim and fill’ sug-
gested trials favoring the placebo may be missing.
Second, endogenous and exogenous testosterone may
have different effects, with endogenous testosterone
being protective, consistent with the observational evi-
dence [1,2] and with testosterone declining with age
when cardiovascular disease increases with age. How-
ever, a recent Mendelian randomization study, using gen-
etic variants as an instrumental variable for endogenous
testosterone, did not corroborate protective effects of
endogenous testosterone on cardiovascular disease risk
factors [69]. Another possibility is that serum testosterone
is not a good indicator of androgen activity [70], as has
long been suggested [71] and recently substantiated by the
effective use of anti-androgens in prostate cancer at cas-
trate levels of serum testosterone [72,73]. Third, endogen-
ous testosterone may be beneficial, but other metabolites
of exogenous testosterone, raised by testosterone therapy,
such as estrogens or dihydrotestosterone, could mediate
cardiovascular-related events. Exogenous estrogens do not
protect men against cardiovascular disease [74]. However,
higher free testosterone rather than higher estradiol
appeared to mediate the cardiovascular events in a recent
trial of testosterone therapy [75]. Few trials have examined
the effects of dihydrotestosterone administration and have
usually focused on prostate rather than cardiovascular
effects [76-78]. The interplay of testosterone and dihydro-
testosterone is complex and challenging to disentangle in
RCTs [79]. Nevertheless, exogenous testosterone lowers
HDL-cholesterol [15] and raises hemoglobin, hematocrit1 10 100
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http://www.biomedcentral.com/1741-7015/11/108and thromboxane [15,80], all of which might contribute to
cardiovascular disease. Thromboxane promotes clotting
and blood vessel constriction. Natural experiments sug-
gest that lower lifetime endogenous androgens are associ-
ated with a relatively lower risk of death from ischemic
heart disease, based on legally castrated men [81] and
men with Klinefelter’s syndrome [82]. Similarly, a meta-
analysis of RCTs of androgen deprivation therapy found a
non-significantly lower risk of cardiovascular mortality
among men allocated to androgen deprivation [83], des-
pite bias to the null by the competing risk of death from
prostate cancer.
Our findings are consistent with the three previous meta-
analyses [13-15], which all indicated a non-significantly
higher risk of testosterone therapy for a composite cardio-
vascular outcome of the events considered, despite discre-
pancies in some studies [13,14]. This meta-analysis based
on many more trials (27), many more men (2,994) and cor-
respondingly more events (180) produced a similar, but
more precise estimate, with the confidence interval no
longer including no effect. The difference between the esti-
mates by funding source is consistent with other observa-
tions [84,85] and could be due to different reporting ofadverse events in industry funded trials. Differences by
funding source could also be due to differences between
trials. Industry funded trials reported fewer cardiovascular-
related events, which reduces power although it should not
affect the direction of effect. Industry funded trials tended
to be in younger men. It is possible, although unusual, for
the effects of treatment to be ‘crossed’ by age [86].
From a clinical perspective the issue is ensuring that the
benefits of testosterone therapy outweigh the potential
risks. Almost a decade after the IOM’s report [12] the effi-
cacy of testosterone therapy for health outcomes where
treatments are not already available remains uncertain.
Testosterone compared to placebo could be beneficial
for glucose metabolism [65], depression [87,88], sexual
dysfunction [26,89], bone density [90] and HIV wasting
syndrome [91,92], although whether testosterone is better
than established treatments for these conditions has not
been clearly established. Cardiovascular disease is com-
mon in typical users of testosterone therapy, that is, older
men. The 10-year risk of a cardiovascular event for US
men aged 65 to 69 years is about 28% [93]. Assuming the
increased risk of cardiovascular-related events seen here
with testosterone therapy would give a number needed to
Xu et al. BMC Medicine 2013, 11:108 Page 9 of 12
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such, further research might focus on obtaining evidence
without interventions, for example by confirming that the
observed negative associations of serum testosterone with
specific cardiovascular diseases extends to other androgen
biomarkers, such as androgen glucuronides [94], and to
other study designs less open to biases, such as Mendelian
randomization. Moreover, a gene in the steroidogenesis
pathway (CYP17A1) is reliably associated with coronary
artery disease [95]. Establishing if CYP17A1 acts, if at all,
by raising or lowering androgens would also bring clarity.
Finally, consideration could be given to whether further
trials should be of agents that raise or lower testosterone.
Strengths and limitations
Despite providing a meta-analysis of all known placebo-
controlled randomized trials, limitations exist. First, the
reporting of adverse events may be open to conflicts of
interest [24]. The funnel plot and analysis by funding
source are consistent with that possibility. A very large
market is at stake [9]. Second, in a trial of a therapy,
such as testosterone, which may change how men feel or
their sex drive, some accidental unmasking may have
occurred. Few trials assessed or reported this possibility.
Third, some men in the testosterone arm stopped
treatment because of increased prostate specific antigen
or polycythemia, which would bias towards the null.
Fourth, RCTs are not always tagged as such and could
be missed [96]. However, we searched broadly and found
several potentially eligible trials that had not been
included in previous meta-analyses. Fifth, our study
cannot include on-going trials, such as the Testosterone
Supplementation and Exercise in Elderly Men trial
(NCT00112151) andTheTestosteroneTrial (NCT00799617).
However, these trials are not designed to assess the effect
of testosterone on cardiovascular events and will take time
to complete. If new trials show testosterone therapy to be
strongly protective against cardiovascular disease, it would
be against the general run of evidence to date making
interpretation uncertain because of heterogeneity [97].
Sixth, the abstractors were not blinded. Seventh, most
trials only reported fairly serious cardiovascular-related
events, but the severity varied between trials, although for
RCTs the reporting of events should be comparable within
trials, and the events reported are more or less severe
symptoms of cardiovascular disease on the pathway to
cardiovascular mortality. An analysis restricted to events
which could be identified as serious gave a similar esti-
mate, but was limited by relying on events the authors
had chosen to describe in detail by study arm and was re-
vised upwards by trim and fill. Arguably, the standard
definitions of event seriousness, including hospitalization,
do not apply to frail older men, because they may be par-
ticularly prone to hospitalization. On the other hand, frailolder people may also be most affected by any decrement
to their already poor health, so hospitalization may repre-
sent a particularly significant event. Notably, an estimate
based solely on deaths also had a similar point estimate,
although the confidence interval included no effect be-
cause of low power. Eighth, two larger trials were termi-
nated early [49,50] which reduces power and could affect
the estimates. However, the terminations took place to-
wards the end of the planned trials and did not specifically
concern cardiovascular-related events. Nevertheless, early
terminations may have slightly increased the estimate and
widened the confidence intervals. However, the inter-
pretation would, most likely, have been similar. Ninth, al-
though meta-analyses are a mainstay of evidence-based
medicine they may be less reliable than large RCTs. Meta-
analysis may overstate the benefits of treatment [98]
however, they are less prone to overstate the harms [98].
Subsequent large RCTs rarely reverse the direction of
effect from meta-analysis [99]. Tenth, given the lack of
detailed cardiovascular-event reporting secondary analysis
by type of cardiovascular event was not possible. Such
sub-group analysis would undoubtedly be etiologically
valuable. However, from a public health perspective the
issue is identifying side-effects, where a composite out-
come relating to a particular system (here the cardiovas-
cular system) has been recommended [20]. Finally, the
difference observed by source of funding could just be
chance variation; however, testosterone therapy increased
the risk of cardiovascular-related events overall.Conclusions
Appropriately prescribed testosterone is undoubtedly bene-
ficial. However, caution needs to be exercised to ensure
that the associated health benefits of testosterone therapy
outweigh the potential increased risk of cardiovascular-
related events, particularly in older men where cardiovas-
cular disease is common.Additional files
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